<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02191878</url>
  </required_header>
  <id_info>
    <org_study_id>TKM-HCC-001</org_study_id>
    <nct_id>NCT02191878</nct_id>
  </id_info>
  <brief_title>Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular Carcinoma</brief_title>
  <official_title>Open-Label, Multi-Center, Phase 1, Dose Escalation Study With Phase 2 Expansion Cohort to Determine the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arbutus Biopharma Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arbutus Biopharma Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an open-label, multi-center, phase 1, dose escalation study with a phase 2&#xD;
      expansion cohort to determine the safety, pharmacokinetics and preliminary anti-tumor&#xD;
      activity of intravenous TKM-080301 in subjects with advanced hepatocellular carcinoma (HCC).&#xD;
&#xD;
      This study is being done to:&#xD;
&#xD;
        -  Test the safety and tolerability of TKM-080301 in subjects with advanced hepatocellular&#xD;
           carcinoma&#xD;
&#xD;
        -  Find the highest dose of TKM-080301 that can be given without causing side effects,&#xD;
           called the maximum tolerated dose (MTD).&#xD;
&#xD;
        -  Provide a preliminary assessment of anti-tumor activity of TKM-080301&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design: Open label, multi-center, 3 + 3 dose-escalation study with an expansion cohort&#xD;
      at the maximum tolerated dose (MTD) to investigate safety, tolerability, PK, and preliminary&#xD;
      anti-tumor activity of TKM 080301 in subjects with HCC.&#xD;
&#xD;
      Sequential cohorts of 3 to 6 subjects will receive escalating doses of TKM 080301 according&#xD;
      to a pre-specified dose escalation scheme. Assessment of dose-limiting toxicities (DLTs) will&#xD;
      be made during Cycle 1 to determine the maximum tolerated dose (MTD). Once the MTD level is&#xD;
      established, approximately 20 subjects will be enrolled in an expansion cohort to further&#xD;
      confirm the safety and tolerability of TKM-080301 at the MTD.&#xD;
&#xD;
      Study Population: A minimum of 9 and up to approximately 18 adult male or female subjects&#xD;
      with histologically or cytologically confirmed metastatic or locally advanced inoperable HCC&#xD;
      and a life expectancy of 3 months or more are planned in the dose escalation phase.&#xD;
      Approximately 20 subjects are planned in the expansion cohort.&#xD;
&#xD;
      Study Treatment: TKM-080301 will be administered by intravenous (IV) infusion, once weekly&#xD;
      for 3 consecutive weeks followed by a 1 week rest period. This 28-day treatment period&#xD;
      constitutes 1 cycle.&#xD;
&#xD;
      Subjects who demonstrate clinical benefit without progression per RECIST 1.1 guidelines may&#xD;
      receive treatment beyond 6 cycles if the Investigator considers it is in the best interest of&#xD;
      the subject, and only with the approval of the Medical Monitor. Subjects would then continue&#xD;
      TKM 080301 therapy until withdrawal of consent, disease progression or unacceptable toxicity&#xD;
      occurs.&#xD;
&#xD;
      Pharmacokinetics (PK) Subjects will undergo blood sample collection for PK analysis during&#xD;
      cycles 1 and 2.&#xD;
&#xD;
      Study Duration: Each treatment cycle will have duration of 28 days and each subject will&#xD;
      typically receive up to 6 cycles of treatment. The total duration of the study is expected to&#xD;
      be approximately 28 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD)</measure>
    <time_frame>Up to 6 months after initial dose.</time_frame>
    <description>Laboratory assessments</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Preliminary assessment of anti-tumor activity by Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1)</measure>
    <time_frame>Upon every 2 cycles of treatment for up to 6 months</time_frame>
    <description>Obtain preliminary assessment of anti-tumor activity by Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit Rate at maximum tolerated dose (MTD) in Expansion Cohort</measure>
    <time_frame>Upon completion of treatment of expansion cohort; up to 6 months after last participant is dosed.</time_frame>
    <description>Assessed after completion of Phase 2.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Assessment of Pharmacodynamic Effect</measure>
    <time_frame>Upon completion of cycle 1 and cycle 2 treatment; 1 and 2 months after last participant is dosed in expansion cohort.</time_frame>
    <description>Assessment of target mRNA reduction in participants consenting to pre- and post-treatment tumor biopsies.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Hepatoma</condition>
  <condition>Liver Cancer, Adult</condition>
  <condition>Liver Cell Carcinoma, Adult</condition>
  <arm_group>
    <arm_group_label>Phase 1 Escalation / Phase 2 Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 1 - dose escalation with intravenous infusion of TKM-080301 to determine MTD.&#xD;
Phase 2 - dose expansion at the MTD.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TKM-080301</intervention_name>
    <description>TKM-080301 intravenous infusion</description>
    <arm_group_label>Phase 1 Escalation / Phase 2 Expansion</arm_group_label>
    <other_name>PLK1-HCC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Child-Pugh class of A&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤5.0 × ULN&#xD;
&#xD;
          -  Total bilirubin ≤3.0 mg/dL&#xD;
&#xD;
          -  Platelets ≥75,000 /mL&#xD;
&#xD;
          -  International Normalized Ratio (INR) ≤1.7&#xD;
&#xD;
          -  Subjects must meet the protocol-defined criteria for both hepatitis B virus (HBV) and&#xD;
             hepatitis C virus (HCV) status&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  History of significant cardiovascular disease will be excluded&#xD;
&#xD;
          -  History of liver transplant.&#xD;
&#xD;
          -  Diagnosis of fibrolamellar HCC or tumors of mixed histology.&#xD;
&#xD;
          -  Subjects known to be positive for Human immunodeficiency virus (HIV) infection.&#xD;
&#xD;
          -  Known central nervous system (CNS) or brain metastases.&#xD;
&#xD;
          -  Poorly controlled ascites and/or requirement for therapeutic paracentesis more&#xD;
             frequently than once every 3 months.&#xD;
&#xD;
          -  Symptomatic encephalopathy within 3 months prior to the first dose of TKM-080301&#xD;
             and/or requirement for medication for encephalopathy.&#xD;
&#xD;
          -  Esophageal variceal bleeding within 2 weeks prior to the first dose of TKM-080301.&#xD;
&#xD;
          -  Asthma or chronic obstructive pulmonary disease (COPD) requiring daily medication.&#xD;
&#xD;
          -  Prior therapy with nitrosoureas or mitomycin within 6 weeks prior to the first dose of&#xD;
             TKM-080301.&#xD;
&#xD;
          -  Prior therapy with any biologic chemotherapeutic or investigational drug within 5&#xD;
             half-lives or 3 weeks, whichever is longer prior to the first dose of TKM 080301.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Kowalski, M.D., Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Tekmira Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arizona Clinical Research Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85715</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas City Research Institute</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Cancer Research Centers</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Gyeonggi-do</state>
        <zip>110744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Gyeonggi-do</state>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASAN Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Gyeonggi-do</state>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severence Hospital, Yonsei, University Health System</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National University Hospital</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipei Medical University Hospital, Shuang-Ho Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>China</country>
    <country>Korea, Republic of</country>
    <country>Singapore</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>July 9, 2014</study_first_submitted>
  <study_first_submitted_qc>July 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2014</study_first_posted>
  <disposition_first_submitted>January 14, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>January 14, 2019</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">January 16, 2019</disposition_first_posted>
  <last_update_submitted>January 14, 2019</last_update_submitted>
  <last_update_submitted_qc>January 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Liver Cancer</keyword>
  <keyword>Liver Neoplasms</keyword>
  <keyword>Liver Epithelial Neoplasms</keyword>
  <keyword>Liver Cancer, malignant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

